Beacon Pointe Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.6M | Buy |
200,691
+47,749
| +31% | +$10.6M | 0.23% | 96 |
|
|
2025
Q4 | $34.9M | Buy |
152,942
+24,252
| +19% | +$5.52M | 0.25% | 93 |
|
|
2025
Q3 | $29.8M | Buy |
128,690
+1,335
| +1% | +$272K | 0.25% | 91 |
|
|
2025
Q2 | $23.6M | Buy |
127,355
+4,169
| +3% | +$775K | 0.25% | 93 |
|
|
2025
Q1 | $25.8M | Sell |
123,186
-400
| -0.3% | -$77.8K | 0.29% | 79 |
|
|
2024
Q4 | $22M | Sell |
123,586
-7,157
| -5% | -$1.32M | 0.24% | 98 |
|
|
2024
Q3 | $25.8M | Sell |
130,743
-4,855
| -4% | -$906K | 0.3% | 78 |
|
|
2024
Q2 | $23.3M | Sell |
135,598
-3,166
| -2% | -$524K | 0.28% | 78 |
|
|
2024
Q1 | $25.3M | Sell |
138,764
-22,464
| -14% | -$3.87M | 0.28% | 80 |
|
|
2023
Q4 | $25M | Sell |
161,228
-9,916
| -6% | -$1.45M | 0.3% | 72 |
|
|
2023
Q3 | $25.5M | Buy |
171,144
+67,993
| +66% | +$9.98M | 0.32% | 72 |
|
|
2023
Q2 | $13.9M | Sell |
103,151
-41,745
| -29% | -$6.12M | 0.23% | 102 |
|
|
2023
Q1 | $23.1M | Buy |
144,896
+66,567
| +85% | +$10.2M | 0.39% | 59 |
|
|
2022
Q4 | $12.7M | Buy |
78,329
+137
| +0.2% | +$21K | 0.25% | 98 |
|
|
2022
Q3 | $10.5M | Buy |
78,192
+556
| +0.7% | +$79.8K | 0.23% | 100 |
|
|
2022
Q2 | $11.9M | Sell |
77,636
-30,838
| -28% | -$4.71M | 0.25% | 96 |
|
|
2022
Q1 | $17.6M | Buy |
108,474
+54,046
| +99% | +$7.85M | 0.24% | 101 |
|
|
2021
Q4 | $7.37M | Sell |
54,428
-9,527
| -15% | -$1.13M | 0.19% | 107 |
|
|
2021
Q3 | $6.9M | Buy |
63,955
+22,287
| +53% | +$2.55M | 0.17% | 137 |
|
|
2021
Q2 | $4.69M | Buy |
41,668
+21,553
| +107% | +$2.43M | 0.17% | 124 |
|
|
2021
Q1 | $2.17M | Buy |
20,115
+936
| +5% | +$100K | 0.13% | 138 |
|
|
2020
Q4 | $2.06M | Buy |
19,179
+3,254
| +20% | +$313K | 0.14% | 130 |
|
|
2020
Q3 | $1.4M | Sell |
15,925
-1,092
| -6% | -$103K | 0.13% | 134 |
|
|
2020
Q2 | $1.67M | Sell |
17,017
-789
| -4% | -$69.5K | 0.17% | 115 |
|
|
2020
Q1 | $1.35M | Buy |
17,806
+11,978
| +206% | +$1.02M | 0.22% | 100 |
|
|
2019
Q4 | $516K | Buy |
5,828
+2,229
| +62% | +$185K | 0.16% | 127 |
|
|
2019
Q3 | $271K | Buy |
3,599
+572
| +19% | +$39.2K | 0.12% | 140 |
|
|
2019
Q2 | $220K | Sell |
3,027
-913
| -23% | -$71.8K | 0.08% | 182 |
|
|
2019
Q1 | $317K | Buy |
3,940
+819
| +26% | +$67K | 0.12% | 143 |
|
|
2018
Q4 | $287K | Buy |
+3,121
| New | +$274K | 0.17% | 127 |
|
Other funds holding ABBV
VCM
VPM
Beacon Pointe Advisors's ABBV Position: Q1 2026 in Review
Beacon Pointe Advisors increased its AbbVie (ABBV) stake by 31% in Q1 2026, buying an estimated $10.6M and bringing the position to 200,691 shares worth $43.6M. The position accounts for 0.23% of the portfolio, ranked #96.
Beacon Pointe Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Beacon Pointe Advisors held 200,691 shares of AbbVie worth $43.6M as of Q1 2026.
- Beacon Pointe Advisors bought 47,749 AbbVie shares in Q1 2026, an estimated $10.6M.
- AbbVie made up 0.23% of Beacon Pointe Advisors's portfolio in Q1 2026, its #96 holding.
- Beacon Pointe Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.